VEGFA and glioblastoma: Bevacizumab is a humanized monoclonal antibody against VEGF, which was granted approval by the US Food and Drug Administration authority in 2009 for its use in recurrent GBM (Presta et al., 1997; Gerber and Ferrara, 2005).